The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don't have diabetes, whether or not they also have impaired kidney function, according to new research to be presented at this year's Annual Meeting of...
Semaglutide's cardiovascular benefits are maintained in people with impaired kidney function, research finds retrieved 11 September 2024 from https://medicalxpress.com/news/2024-09-semaglutide-cardiovascular-benefits-people-impaired.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Aug 28, 2024Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Semaglutide-linked suicidal ideation identified in disproportionality analysisSemaglutide-associated suicidal ideation has been identified in a disproportionality analysis, according to a study published online Aug. 20 in JAMA Network Open.
Read more »
Clarification urgently needed for detected signal of semaglutide-linked suicidal ideationResearchers investigate the potential link between the obesity drugs semaglutide and liraglutide and suicidal or self-injurious adverse drug reactions.
Read more »
Study warns of high Medicare costs for semaglutide even with restrictive CVD definitionIf Medicare Part D narrowly defines cardiovascular disease, the majority of patients would remain ineligible while new federal spending could still exceed $10 billion
Read more »
Semaglutide shown to cut major adverse cardiovascular events in heart failure patientsSemaglutide shows promise in reducing cardiovascular risks in obese patients with heart failure, improving outcomes in a recent large-scale clinical trial.
Read more »
Semaglutide reduces risk for major adverse cardiovascular events in patients with obesity and heart failureSemaglutide reduces the risk for major adverse cardiovascular events (MACE) and composite heart failure end points compared with placebo in patients with overweight or obesity and heart failure, according to a study published online Aug. 24 in The Lancet.
Read more »
Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patientsA study published in eClinicalMedicine found that tirzepatide outperforms semaglutide in reducing the risk of type 2 diabetes and major cardiovascular events among individuals with obesity, with or without existing diabetes, while also achieving greater weight loss.
Read more »